✨ Free AI Report
Harmony Biosciences Holdings, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Harmony Biosciences Holdings, Inc.
Research Preview

Harmony Biosciences Holdings, Inc.: Business Overview, Financials & Competitive Analysis

Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. The company's flagship product, WAKIX (pitolisant), tr...

Analyst-debate audio for Harmony Biosciences Holdings, Inc.

AskCyborg analysts argue the bull and bear cases for Harmony Biosciences Holdings, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Harmony Biosciences Holdings, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
8/ 10Strong

Cyborg Score thesis

Rare disease pharma with proven blockbuster drug, expanding pipeline into multiple indications, and strong revenue growth...

Read the full analyst-debate transcript →
Industry Pharmaceuticals - Rare/Specialty Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest Harmony Biosciences Holdings, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Harmony Biosciences Holdings, Inc. Overview

Pro stress-test →

Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. The company's flagship product, WAKIX (pitolisant), treats excessive daytime sleepiness in adult patients with narcolepsy and is on track for blockbuster status.

Strategic Profile

Pro stress-test →

WAKIX generated $868 million in 2025 preliminary revenue with 2026 guidance of $1.0-$1.04 billion, demonstrating strong commercial execution. The company is expanding pitolisant across multiple neurological indications including Prader-Willi Syndrome in Phase 3 trials and Myotonic Dystrophy in Phase 2, while evaluating broader applications for H3 receptor-mediated disorders.

Competitive Landscape

Pro stress-test →

Harmony is positioned in the rare neurological disease market with an expanding addressable market and diversified pipeline. Primary competition comes from other narcolepsy and rare neurological disease specialists, with Harmony's competitive advantage centered on WAKIX's novel H3 receptor mechanism and expanding multi-indication pipeline.

Industry Context

Harmony Biosciences Holdings, Inc. operates in Pharmaceuticals - Rare/Specialty Diseases.

Key facts

Founded: 2017 · Headquarters: Plymouth Meeting, Pennsylvania, United States · Employees: 293 · Revenue: $868M (2025 preliminary) · Market cap: $1.644B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Harmony Biosciences Holdings, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Harmony Biosciences Holdings, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Narcolepsy TreatmentsAlternative narcolepsy medications→Rare Neurological DisordersRare genetic neurological disease treatments→Epilepsy TreatmentsRare epilepsy and seizure disorder medications→

Compare Harmony Biosciences Holdings, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Harmony Biosciences Holdings, Inc. operates in Pharmaceuticals - Rare/Specialty Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals - Rare/Specialty Diseases research →
NEW · MCP server

Ask your AI assistant about Harmony Biosciences Holdings, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Harmony Biosciences Holdings, Inc. and its top competitor on Cyborg Score”
“What did Harmony Biosciences Holdings, Inc. do this quarter?”
“Is Harmony Biosciences Holdings, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Harmony Biosciences Holdings, Inc. do?+
Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. The company's flagship product, WAKIX (pitolisant), tr...
What is Harmony Biosciences Holdings, Inc.'s Cyborg Score?+
Harmony Biosciences Holdings, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Harmony Biosciences Holdings, Inc.'s main competitors?+
Named competitors include Narcolepsy Treatments, Rare Neurological Disorders, Epilepsy Treatments. The full competitive landscape is in the AskCyborg report.
How can I get the full Harmony Biosciences Holdings, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Harmony Biosciences Holdings, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Harmony Biosciences Holdings, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9GELEX Group Joint Stock Company9TTM Technologies, Inc.9Insulet Corporation9Marathon Petroleum Corporation9Seagate Technology Holdings plc9Howmet Aerospace Inc.9Investor AB9Micron Technology, Inc.9Taiwan Semiconductor Manufacturing Company Limited9NVIDIA Corporation8NIO Inc.8Seanergy Maritime Holdings Corp.8Grupo Aeroméxico, S.A.B. de C.V.8Gulf Medical Projects Company8Interloop Limited8Kyverna Therapeutics, Inc.8Tatton Asset Management Plc8Invictus Investment Company PLC